Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Fortis Therapeutics logo — Pioneering antibody-drug conjugate therapies to combat late-...

Fortis Therapeutics

Pioneering antibody-drug conjugate therapies to combat late-stage multiple myeloma and prostate cancer.

Founded 2016 Series A Total: $58.00M Biotechnology, Health and Wellness

General Information

Company Name Fortis Therapeutics
Founded Year 2016
Industries Biotechnology, Health and Wellness
Funding Stage Series A
Social

Get notified when Fortis Therapeutics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Fortis Therapeutics

Fortis Therapeutics is a pioneering immuno-oncology biotech startup founded in 2016. The company's focus lies in developing revolutionary antibody-drug conjugate therapies that target CD46, particularly for combating late-stage multiple myeloma and late-stage prostate cancer, as well as other indications. The recent noteworthy activity for Fortis Therapeutics is a substantial $40.00M Series A investment that took place on 29 March 2021. The investment was led by a consortium of prominent investors, including Avalon Ventures, Lilly Asia Ventures, Vivo Capital, Myeloma Investment Fund, Fulcrum 2020, Bregua, and OUP (Osage University Partners). This indicates considerable confidence from reputable investors in the potential of the startup's innovative approach within the Biotechnology and Health and Wellness industries.

Taxonomy: immuno-oncology, biotech, antibody-drug conjugate, CD46, multiple myeloma, prostate cancer, late-stage, therapies, oncology research, drug development

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series A •••••• 7
Investor Investor Investor Investor
•••• •••• 		29 Mar 2021
Series A •••••• 3
Investor Investor
•••• •••• 		27 Sep 2016

Fortis Therapeutics Alternatives & Competitors

Fortis Therapeutics vs
BioSapien
BioSapien United States

Developing innovative therapies to transform patient care. Inventor of the MediChip®.

Grant
12 employees
Biopharma, Biotechnology
Fortis Therapeutics vs
Cumulus Oncology
Cumulus Oncology United Kingdom

Finding assets, creating spin-outs, commercialising cancer therapies.

16 employees
Fortis Therapeutics vs
Centessa Pharmaceuticals
Centessa Pharmaceuticals

A new kind of pharmaceutical company delivering asset centricity at scale.

Acquired
151 employees
Biotechnology, Pharmaceutical

FAQ About Fortis Therapeutics

Pioneering antibody-drug conjugate therapies to combat late-stage multiple myeloma and prostate cancer.
Fortis Therapeutics was founded in 2016.
Fortis Therapeutics operates in the following industries: Biotechnology, Health and Wellness.
Fortis Therapeutics has completed 2 funding rounds, raising a total of $58.00M. The latest funding stage is Series A.
Top alternatives and competitors to Fortis Therapeutics include BioSapien, Cumulus Oncology, Centessa Pharmaceuticals, Nerviano Medical Sciences - Part of NMS Group, BioVaxys Technology Corp.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Fortis Therapeutics and BioSapien are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Fortis Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy